Company intelligence / Profile preview

Mersifarma

Sukabumi, West Java, Indonesia

Ownership: Private
Employees: ~1000
Development stage: Other

Overview

Mersi is a major Indonesian pharmaceutical manufacturer and distributor, especially strong in CNS drugs, and is aligned with international GMP standards; details of specific clinical-stage innovative products or targeted therapeutic results are not disclosed.

Therapeutic areas: NeurologyOther
Modalities: Small moleculeHealth supplementsBiologic
Industry: Biotech

Partnerships

Reputable pharmaceutical companies in Indonesia for "Toll Manufacturing" (contract manufacturing)

Beyond the preview

Go deeper on Mersifarma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mersifarma.

Explore the full profile